L
Lisa Janine Hammond
Researcher at Eli Lilly and Company
Publications - 4
Citations - 2030
Lisa Janine Hammond is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: FGF21 & Diabetes mellitus. The author has an hindex of 4, co-authored 4 publications receiving 1825 citations.
Papers
More filters
Journal ArticleDOI
FGF-21 as a novel metabolic regulator
Alexei Kharitonenkov,Tatiyana L. Shiyanova,Anja Koester,Amy M. Ford,Radmila Micanovic,Elizabeth Galbreath,George E. Sandusky,Lisa Janine Hammond,Julie S. Moyers,Owens Rebecca Anne,Jesper Gromada,Joseph T. Brozinick,Eric D. Hawkins,Victor J. Wroblewski,De Shan Li,Farrokh Mehrbod,S. Richard Jaskunas,Armen B. Shanafelt +17 more
TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Patent
Method for treating diabetes and obesity
TL;DR: A method for treating diabetes and obesity comprising administering an effective amount of fibroblast growth factor 21 is described in this paper, which is used to treat the symptoms of obesity and diabetes.
Patent
Treating musculoskeletal disorders using lp85 and analogs thereof
John Michael Beals,Patricia Gonzalez-DeWhitt,Lisa Janine Hammond,Jirong Lu,Songqing Na,Eric Wen Su,Derrick Ryan Witcher,Victor J. Wroblewski +7 more
TL;DR: In this article, the authors proposed methods for treating or preventing osteoporosis, osteopenia, sarcopenia and arthritis in a mammal which comprise the administration of a therapeutically effective amount of a pharmaceutical composition comprising a LP85 polypeptide or LP85 analog.
Patent
Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
Janet Mary Hock,Songqing Na,Lisa Janine Hammond,Alexei Kharitonenkov,Venkatesh Krishnan,Gerald Wayne Becker +5 more
TL;DR: In this article, the authors provide compositions and methods for treating osteopenia, osteoporosis, arthritis, sarcopenia and peridontal disease or promoting bone growth comprising the administration of a therapeutically effective amount of LP8.